The basic criteria taken into account when qualifying patients for PCa brachytherapy are the PSA (prostate-specific antigen) concentration, tumor differentiation according to the Gleason classification, and TNM clinical stage [3,4,5]. Here, KLK3 is linked to neoplasm.